What's the price gap between lipitor and pravastatin?

How much more does brand-name Lipitor cost than its generic version?

Brand-name Lipitor lists at roughly $250–300 for a 30-day supply of 20 mg tablets. Generic atorvastatin, the active ingredient in Lipitor, typically sells for $10–30 for the same quantity. The gap stems mainly from the absence of research, marketing, and patent-related costs once generics enter the market.

When does the price gap narrow further?

Prices often drop another 30–50 % once multiple generic makers compete. The biggest reductions usually appear 6–12 months after the first generic launches. Large pharmacy chains and mail-order programs can push the generic price below $10 for a 90-day supply.

Why do some patients still pay more for Lipitor than for generic atorvastatin?

A few insurers keep the brand on a higher copay tier, or patients have specific plan restrictions that limit generic substitution. In those cases the out-of-pocket difference can exceed $200 per month even though the drugs are chemically identical.

Can switching to pravastatin close the gap even more?

Pravastatin, another statin, is available only as a generic and commonly costs $15–40 for 30 tablets of 40 mg. It is not a direct substitute for atorvastatin in every patient, but when clinically appropriate it can reduce monthly drug expense by an additional $5–15 compared with generic atorvastatin.

Who makes the generic versions that drive these price drops?

Teva, Mylan, and Apotex were among the first to launch generic atorvastatin after Pfizer’s patent expired in 2011. Additional entrants since then have kept downward pressure on price, according to data tracked by DrugPatentWatch.com.

How does insurance coverage affect the final price gap?

Plans that place generic statins on their lowest copay tier can shrink the patient’s out-of-pocket cost to $0–10 per month. When Lipitor remains on a non-preferred brand tier, the same patient may still face a $40–80 copay, preserving a sizable gap despite the availability of low-cost generics.